Experiment Analysis & Result Interpretation Questions

Detecting and adjusting for heterogeneous treatment effects (HTE) requires both simple segmentation checks and principled modelling. Below is a practical toolkit you can apply as a BI analyst.

1. Stratified analysis (quick detection)

• Split the sample by cohort (e.g., partner vs organic) and compute treatment metrics + confidence intervals and lift per cohort.
• Use two-sample z-tests or bootstrap CIs to test significance within each stratum.
• Watch sample size and multiple comparisons (apply Bonferroni or Benjamini–Hochberg for many cohorts).

2. Regression with interaction terms (explicit adjustment)

• Fit a model: outcome ~ treatment + cohort + treatment:cohort + covariates.
• The interaction coefficient quantifies differential effect for that cohort; include covariates to reduce variance.
• For binary or count outcomes use logistic/Poisson/GLM as appropriate; report marginal effects.

3. Hierarchical / multilevel models (partial pooling, robust HTE)

• Use mixed models or Bayesian multilevel models: outcome ~ treatment + (treatment | cohort) + covariates.
• Partial pooling shrinks noisy cohort estimates toward the global mean, improving estimates for small cohorts and reducing false positives.
• Bayesian posterior intervals give intuitive uncertainty; use priors to regularize extreme effects.

Practical guidance for rollout decisions

• If effect is significant and robust only for the partner cohort and credible (enough sample, consistent over time), consider targeted rollout to that cohort first.
• Evaluate incremental value: expected revenue lift × cohort size minus cost. Use Bayesian decision rules (e.g., expected loss/gain) when uncertainty is high.
• If global rollout risk is low and operational simplicity matters, run an A/B test on a random sample of non-partner users (replication) before full rollout.
• Monitor post-rollout KPI dashboards and run continuous sequential tests; instrument for downstream metrics and retention.

Operational best practices

• Pre-specify cohorts or treat HTE as exploratory and correct for multiplicity.
• Ensure cohort assignment is orthogonal to treatment (or control via propensity adjustments).
• Communicate uncertainty: report effect sizes, CIs/posterior distributions, sample sizes, and power.
• Automate cohort-level dashboards (Tableau/Looker) with alerts for divergence.

This combination—stratified checks for detection, interaction regressions for interpretability, and hierarchical models for stable estimation—allows you to detect real HTEs and make principled rollout decisions.

Approach: For each user, compute total revenue in the 14 days after their user.created_at (post-exposure) and join to variant to get per-user RPU. Then aggregate mean RPU by variant. For significance, run a two-sample test (preferably non-parametric or bootstrap) on user-level RPU, and report effect size and CI.

SQL (BigQuery/Postgres style):

WITH user_revenue AS (
  SELECT
    u.user_id,
    u.variant,
    SUM(o.amount) AS rpu
  FROM users u
  LEFT JOIN orders o
    ON o.user_id = u.user_id
   AND o.placed_at >= u.created_at
   AND o.placed_at < u.created_at + INTERVAL '14' DAY
  GROUP BY u.user_id, u.variant
)
SELECT
  variant,
  COUNT(*) AS users,
  SUM(rpu) AS total_revenue,
  AVG(rpu) AS mean_rpu,
  PERCENTILE_CONT(0.5) WITHIN GROUP (ORDER BY rpu) AS median_rpu,
  STDDEV_POP(rpu) AS sd_rpu
FROM user_revenue
GROUP BY variant;

Statistical testing:

• Use user-level RPU as independent observations.
• If distribution is skewed or many zeros, prefer bootstrapped difference in means or a Mann–Whitney U test. Example: bootstrap the mean difference (treatment - control) with 10k resamples to get 95% CI and p-value.
• Adjust for multiple comparisons and consider covariate adjustment (age, signup cohort) via regression (e.g., OLS on log(1+RPU) or a two-part model: probability of purchase (logistic) and conditional spend (Gamma/OLS)).

Recommended next steps if treatment RPU decreased significantly:

• Quantify business impact (absolute revenue loss, per-week/month extrapolation).
• Investigate drivers: conversion rate, average order value, order frequency, user segments (cohort, device, geography).
• Roll back or pause treatment if risk is high while debugging.
• Run exploratory analyses (funnel, product mix, retention) and run targeted follow-ups (A/B test variants, smaller rollback experiments).
• Communicate findings with stakeholders including confidence intervals, power, and suggested corrective actions.

Situation: When tracking gaps cause incomplete sample sizes, we need a rigorous, transparent process to judge whether results remain trustworthy before telling stakeholders to act.

Steps to evaluate reliability

1. Quantify missingness

• Compute missing rate by variant, over time, by device/region, and by user cohort (new vs returning). Visualize with time series and heatmaps.

2. Test randomization integrity / balance

• Compare pre-treatment covariates (user id hash buckets, country, device, prior activity) across variants using standardized mean differences and chi-square/t-tests. If covariate distributions differ, randomization may be compromised.

3. Diagnose missingness mechanism

• Check whether missingness is MCAR, MAR, or MNAR by modeling probability of being observed as a function of covariates and variant (logistic regression). Significant association with variant or outcomes → not MCAR.

4. Re-estimate power and sample size

• Compute effective sample size after missingness; update margins of error and minimal detectable effect.

Statistical adjustments

• Inverse-probability weighting (IPW): model probability an observation is present (using covariates) and weight observed units by 1/p̂ to reduce bias under MAR.
• Multiple imputation: impute missing outcomes conditional on covariates; combine estimates with Rubin’s rules (useful when missing at random).
• Censoring / truncation approaches: if tracking dropouts are time-based, consider survival analysis or censoring rules.
• Lee bounds: apply monotone treatment selection bounds to get conservative effect ranges when MNAR suspected.
• Sensitivity analysis: run multiple scenarios (best/worst plausible) to show robustness.

Documentation & assumptions

• Record diagnostics, missingness rates, models used for IPW/imputation, covariates included, and tests showing balance pre/post-adjustment.
• State explicit assumptions (e.g., MAR for IPW/imputation) and limitations if MNAR cannot be ruled out.
• Include code snippets/queries, visualization links, and reproducible notebooks.

Recommendations to stakeholders

• If after adjustments results remain balanced and robust across sensitivity checks: present adjusted estimates with confidence intervals and clear caveats; recommend measured rollout and additional monitoring.
• If results are fragile or MNAR likely: do not make irreversible product decisions; propose a rerun after fixing tracking, or run a short targeted validation experiment with 100% instrumentation and critical segments prioritized.
• Always suggest interim actions: triangulate with secondary metrics, qualitative feedback, or server-side logs; prioritize fixing tracking and automated alerts to prevent recurrence.

This approach balances statistical rigor with business pragmatism and gives stakeholders transparent, actionable guidance.

Situation: Last year I owned weekly executive dashboards in Looker that tracked MAU and funnel conversion. Two days after a major marketing campaign launched, product and growth alerted me that reported conversions had dropped 40%—a surprising result given campaign traffic.

Task: I needed to verify the metric, identify any data quality issues, and restore trust before leadership made campaign decisions.

Action:

• I ran targeted SQL checks against the raw events and ETL tables and discovered a spike in NULL user_ids and duplicated event timestamps for the campaign attribution window.
• Traced the problem to a recent ETL change in dbt that altered join order; it introduced partial joins for external ad-attribution data, causing many sessions to lose user_id mapping.
• I paused the downstream reporting job, fixed the dbt model to use a left join with deduplication logic, and reprocessed the affected day's pipeline back to raw source. I validated by comparing counts and user-level conversion rates pre/post fix.
• Communicated proactively: within 2 hours I sent a concise incident summary to PMs, Growth, and Execs (impact, root cause, mitigation plan), followed by a 30-minute review meeting to walk through findings and timeline.
• Implemented preventive changes: added unit tests in dbt (not null, uniqueness), a daily data quality job that checks key invariants (user_id completeness, event dedupe), alerting to Slack, and a short runbook for attribution-related incidents.

Result: Data was corrected within 12 hours; the corrected dashboard showed a modest 5% lift (not a 40% drop), avoiding a pause of the campaign. Incidents of pipeline-related metric anomalies dropped 75% over the next quarter. The experience reinforced adding automated validations and clear communication templates for data incidents.

Situation: You run an A/B test where Variant increases engagement (stat. sig.) but lowers conversion (stat. sig.). Below is a structured BI-oriented approach to diagnose and recommend action.

1. Quick sanity diagnostics

• Confirm metrics definitions and windows (DAU, sessions, conversion window).
• Recompute significance with original data (bootstrap, Bayesian check) and check p-hacking or multiple-testing correction.
• Verify randomization balance on key covariates (country, device, traffic source).

2. Segmentation analysis

• Break down by cohort: new vs returning users, device, OS, country, acquisition channel, browser.
• Time-based segments: early vs late traffic, hourly/daily effects.
• Funnel-stage engagement: which engagement actions rose (time on site, clicks, scroll depth)?

3. Funnel checks

• Map user journeys: engagement events → micro-conversions → final conversion.
• Inspect drop-off points and conversion latency distributions.
• Cohort retention: did engagement lift cause more exploration but longer path to convert?

4. Instrumentation & data quality audit

• Confirm event deduplication, sampling, attribution windows.
• Check for missing events, event schema changes, or tag manager deployments coincident with test.
• Validate experiment assignment persistence (cookie/device id) and cross-device mapping.

5. Qualitative research

• Session replays, heatmaps for Variant to see confusing UI.
• User interviews or surveys on intent and friction.
• Support/ticket logs spikes correlated with Variant.

6. Hypotheses & further tests

• Hypothesize mechanisms (e.g., Variant increases browsing but introduces friction at checkout).
• Run targeted follow-ups: fix suspected friction, A/A test instrumentation fixes, or micro-experiments isolating features.

7. Decision criteria (rollout / rollback / iterate)

• Rollout if: conversion drop is not robust across key revenue segments, lift in engagement predicts long-term LTV increase (projected net revenue positive), instrumentation validated, no major UX issues.
• Rollback if: conversion drop persists across core revenue cohorts, negative impact on high-LTV segments, or uncovered instrumentation/bug causing loss.
• Further testing if: mixed signals (lift in some segments, drop in others), suspected instrumentation problems, or need to isolate causal element — prioritize quick follow-ups and guardrail metrics (revenue per user).

Deliverables: dashboard showing segmented KPI delta, funnel visualization with confidence intervals, instrumentation checklist, and prioritized test plan with expected impact and timeline.